Business Context and Reporting Period
Liquidia Corporation (LQDA) is a biopharmaceutical company focused on rare cardiopulmonary diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company operates through subsidiaries Liquidia Technologies and Liquidia PAH. Current revenue is derived from a promotion agreement with Sandoz for generic treprostinil injection. The company's lead product candidate, YUTREPIA (an inhaled treprostinil), has received tentative FDA approval for PAH and is awaiting final action, with an amended NDA pending for PH-ILD. This filing covers the fiscal quarter ended June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $3.7 million | $4.8 million | $6.6 million | $9.3 million |
| Net Loss | $(27.9) million | $(23.5) million | $(68.9) million | $(35.3) million |
| Loss Per Share (Basic/Diluted) | $(0.37) | $(0.36) | $(0.91) | $(0.54) |
| Cash and Cash Equivalents | $133.1 million | $88.2 million (Q2 2023) | $133.1 million (Balance Sheet) | $93.3 million (Dec 31, 2023) |
| Revenue Interest Financing Payable | $86.0 million (Total) | $46.0 million (Total) | $86.0 million (Total) | $46.0 million (Total) |
| Accumulated Deficit | $(498.0) million | $(385.9) million | $(498.0) million | $(385.9) million |
Note: Revenue interest financing payable includes $4.2 million current and $81.8 million non-current as of June 30, 2024.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 24% in Q2 and 29% YTD compared to the prior year, primarily due to lower sales quantities of Treprostinil Injection driven by shortages of the CADD-MS 3 infusion pumps required for administration.
- Expense Increases: General and Administrative (G&A) expenses surged 116% in Q2 and 136% YTD, driven by sales force expansion in anticipation of YUTREPIA launch, increased commercial consulting, and higher legal fees related to ongoing litigation.
- Debt Restructuring: The company recorded a $11.5 million loss on extinguishment of debt in Q1 2024 following an amendment to its Revenue Interest Financing Agreement (RIFA) with HCR, which increased the funded amount and adjusted payment terms.
- Inventory Capitalization: The company capitalized $7.2 million of prelaunch inventory for YUTREPIA in Q2 2024, whereas no such inventory was capitalized in the prior year.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the issuance date, excluding potential YUTREPIA sales or external financing. The company expects to require additional capital to fund operations and meet RIFA covenants.
- Regulatory Status: YUTREPIA awaits final FDA approval. The company is awaiting a decision on a Supreme Court petition regarding the validity of a patent held by United Therapeutics that previously blocked approval. An injunction blocking approval was set aside in March 2024, but United Therapeutics has appealed this decision.
- Litigation Risks: Significant ongoing litigation with United Therapeutics involves patent infringement claims, trade secret misappropriation allegations, and challenges to the FDA's acceptance of the YUTREPIA NDA. Outcomes could materially delay or prevent commercialization.
- Supply Chain Constraints: Sales of current revenue-generating products are constrained by the limited availability of Smiths Medical's CADD-MS 3 pumps, which are no longer manufactured. A new pump is in development with Mainbridge, with FDA clearance anticipated in 2025.
- Debt Covenants: The RIFA requires maintaining minimum cash balances of $7.5 million for 2024 and $15.0 million thereafter. Failure to meet these covenants could trigger acceleration of debt payments.
Investor Verification Checklist
- Supreme Court Petition: Monitor the status of United Therapeutics' petition for a writ of certiorari regarding the '793 Patent, expected to be considered by the Supreme Court in late September 2024.
- FDA Approval Timeline: Verify the final decision timeline for YUTREPIA's NDA, particularly regarding the PH-ILD indication and the impact of the pending appeals on the injunction.
- Liquidity Runway: Assess the company's ability to meet the $7.5 million minimum cash covenant under the RIFA given the current burn rate and operating losses.
- Pump Availability: Confirm the progress of the new infusion pump development with Mainbridge and the timeline for FDA 510(k) clearance to mitigate current revenue constraints.
- Capital Raising: Evaluate the likelihood and terms of potential future equity or debt financing required to sustain operations beyond the current cash position.